Clinical results of EGFR-targeted therapies in advanced colorectal cancer

Evaristo Maiello; Vittorio Gebbia; Luigi Manzione; Francesco Giuliani; Franco Morelli; Carlo Arcara; Antonio Grimaldi; Giuseppe Colucci

doi:10.1016/j.ejcsup.2008.06.014

Clinical results of EGFR-targeted therapies in advanced colorectal cancer

Evaristo Maiello, Vittorio Gebbia, Luigi Manzione, Francesco Giuliani, Franco Morelli, Carlo Arcara, Antonio Grimaldi, Giuseppe Colucci

Research output: Contribution to journal › Article › peer-review

Abstract

This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents - cetuximab and panitumumab - employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens - FOLFIRI and FOLFOX - has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects.

Original language	English
Pages (from-to)	64-69
Number of pages	6
Journal	European Journal of Cancer, Supplement
Volume	6
Issue number	14
DOIs	https://doi.org/10.1016/j.ejcsup.2008.06.014
Publication status	Published - Oct 2008

Keywords

Cetuximab
Colorectal cancer
Panitumumab

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1016/j.ejcsup.2008.06.014

Fingerprint Dive into the research topics of 'Clinical results of EGFR-targeted therapies in advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this

@article{2288c3e69bb44d38b84a0bde3e814358,

title = "Clinical results of EGFR-targeted therapies in advanced colorectal cancer",

abstract = "This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents - cetuximab and panitumumab - employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens - FOLFIRI and FOLFOX - has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects.",

keywords = "Cetuximab, Colorectal cancer, Panitumumab",

author = "Evaristo Maiello and Vittorio Gebbia and Luigi Manzione and Francesco Giuliani and Franco Morelli and Carlo Arcara and Antonio Grimaldi and Giuseppe Colucci",

year = "2008",

month = oct,

doi = "10.1016/j.ejcsup.2008.06.014",

language = "English",

volume = "6",

pages = "64--69",

journal = "European Journal of Cancer, Supplement",

issn = "1359-6349",

publisher = "Elsevier Limited",

number = "14",

}

TY - JOUR

T1 - Clinical results of EGFR-targeted therapies in advanced colorectal cancer

AU - Maiello, Evaristo

AU - Gebbia, Vittorio

AU - Manzione, Luigi

AU - Giuliani, Francesco

AU - Morelli, Franco

AU - Arcara, Carlo

AU - Grimaldi, Antonio

AU - Colucci, Giuseppe

PY - 2008/10

Y1 - 2008/10

N2 - This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents - cetuximab and panitumumab - employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens - FOLFIRI and FOLFOX - has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects.

AB - This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents - cetuximab and panitumumab - employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens - FOLFIRI and FOLFOX - has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects.

KW - Cetuximab

KW - Colorectal cancer

KW - Panitumumab

UR - http://www.scopus.com/inward/record.url?scp=55649096649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649096649&partnerID=8YFLogxK

U2 - 10.1016/j.ejcsup.2008.06.014

DO - 10.1016/j.ejcsup.2008.06.014

M3 - Article

AN - SCOPUS:55649096649

VL - 6

SP - 64

EP - 69

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 1359-6349

IS - 14

ER -